AlphaMark Advisors’s GSK GSK Stock Holding History

AlphaMark Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-100	Closed	-$4K	–	632
2022 Q4	$4K	Buy	100 +28	+39%	+$933	﹤0.01%	466
2022 Q3	$2K	Hold	72	–	–	﹤0.01%	594
2022 Q2	$4K	Hold	72	–	–	﹤0.01%	489
2022 Q1	$4K	Hold	72	–	–	﹤0.01%	498
2021 Q4	$4K	Hold	72	–	–	﹤0.01%	474
2021 Q3	$3K	Sell	72 -8	-10%	-$402	﹤0.01%	510
2021 Q2	$4K	Hold	80	–	–	﹤0.01%	475
2021 Q1	$4K	Hold	80	–	–	﹤0.01%	459
2020 Q4	$4K	Hold	80	–	–	﹤0.01%	433
2020 Q3	$4K	Hold	80	–	–	﹤0.01%	449
2020 Q2	$4K	Buy	80 +56	+233%	+$2.87K	﹤0.01%	448
2020 Q1	$1K	Buy	+24	New	+$1.28K	﹤0.01%	519

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AlphaMark Advisors's GSK Position: Q1 2023 in Review

AlphaMark Advisors sold out of GSK (GSK) in Q1 2023, closing a stake of 100 shares — an estimated $4K sold.

AlphaMark Advisors first reported a position in GSK in Q1 2020 and held it in 12 quarters. The position peaked at $4K in Q4 2022. 809 funds tracked by Wall St. Rank hold GSK as of Q1 2023.

AlphaMark Advisors reported no remaining GSK position as of Q1 2023 after selling out during the quarter.
AlphaMark Advisors sold 100 GSK shares in Q1 2023, an estimated $4K.
AlphaMark Advisors first reported a position in GSK in Q1 2020 and held it in 12 quarters.
AlphaMark Advisors's GSK position peaked at $4K in Q4 2022.
809 funds tracked by Wall St. Rank held GSK as of Q1 2023.

Based on AlphaMark Advisors's 13F filing for Q1 2023, filed 4 May 2023.